Investigator
Jin-Ming Yang
UNIVERSITY OF KENTUCKY · funded by NCI
- Companies
- 1
- Grants
- 2
- Non-dilutive funding
- $822k
- First award
- Mar 1, 2024
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Apr 1, 2024.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- APLEXIS, INC.81momentum
OncologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R01
Integrative Targeted Therapy for Melanoma
$609kApr 1, 2024NCIUNIVERSITY OF KENTUCKYNIH RePORTER · 11060916 (opens the source filing in a new tab)
- R21
Novel Strategy to Augmenting Immunotherapy against Melanoma
$213kMar 1, 2024NCIUNIVERSITY OF KENTUCKYNIH RePORTER · 11045672 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources